Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma
Jan‐Malte Placke(Düsseldorf University Hospital), Selma Ugurel(Klinikum Bielefeld), Jochen Utikal(German Cancer Research Center), Edgar Dippel(Klinikum Ludwigshafen), Rudolf Herbst(Helios Klinikum Erfurt), Klaus Griewank(Düsseldorf University Hospital), Ralf Gutzmer(University Hospitals of the Ruhr-University of Bochum), Susanne Horn(Vrije Universiteit Brussel), Michael Weichenthal(Christian-Albrechts-Universität zu Kiel), Claudia Pföhler(Saarland University), Alexander Roesch(Essen University Hospital), Dirk Schadendorf(National Center for Tumor Diseases), Friedegund Meier(National Center for Tumor Diseases), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Georg Lodde(Essen University Hospital), Elisabeth Livingstone(German Cancer Research Center), Antje Sucker(German Cancer Research Center), Daniel R. Engel(Essen University Hospital), Camille Soun(Essen University Hospital), Lisa Zimmer(The University of Sydney), Jürgen C. Becker(Düsseldorf University Hospital), Christiane Pfeiffer(University Hospital Augsburg), Jenny Bottek(Essen University Hospital), Alexander Kreuter(HELIOS St. Elisabeth Klinik Oberhausen), Eva Hadaschik(West German Heart and Vascular Center Essen), Jens Ulrich, Patrick Terheyden(University Hospital Schleswig-Holstein)
Cited by 19
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k